Global Myocardial Infarction Market Analysis

The Global Myocardial Infarction Market is expected to grow significantly, reaching US$ 3.43 billion by 2032, up from US$ 2.02 billion in 2023, representing a CAGR of 6.06% from 2024 to 2032.

What is Myocardial Infarction?

Myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow to a section of the heart muscle is blocked, leading to damage or death of heart tissue. The blockage is typically caused by plaque buildup in one or more coronary arteries. If blood flow is not restored quickly, the heart muscle may be permanently damaged or lead to fatal consequences. The urgency of treatment is critical, as every minute of delay increases the risk of irreversible heart damage.

Request a free sample copy of the report

Key Global Insights

• In 2021, the World Heart Federation reported that over 50% of the global population is impacted by cardiovascular diseases, causing 20.5 million deaths, making it one of the leading causes of global mortality.

• In June 2023, the FDA approved Lodoco (colchicine), developed by Agepha Pharma, to reduce the risk of myocardial infarction, stroke, and cardiovascular-related deaths. Lodoco is the first drug to target inflammation, a major cause of atherosclerotic cardiovascular disease.

• The NHS launched a campaign in August 2023 encouraging early medical intervention for heart attack symptoms, emphasizing the importance of calling emergency services to prevent life-threatening complications.

United States Myocardial Infarction Market

The U.S. is a significant player in the myocardial infarction market, driven by the increasing prevalence of heart disease, high healthcare expenditures, and advanced medical infrastructure. The country is home to major hospitals like Cleveland Clinic, Mayo Clinic, and New York-Presbyterian, which lead in providing cutting-edge MI treatments. Hybrid operating rooms and advanced treatment technologies have also contributed to market growth in the U.S.

Global Myocardial Infarction Company News

• Major players like Pfizer, Sanofi-Aventis/Bristol-Myers Squibb, AstraZeneca, and Merck continue to dominate the MI market.

• Johnson Johnson is set to present new clinical data on cardiovascular treatments, including XARELTO® (rivaroxaban), at the American College of Cardiology's Annual Scientific Session in April 2024.

• Royal Philips showcased its use of AI in cardiac care to improve clinical accuracy and efficiency during August 2023.

• In November 2022, Johnson Johnson acquired Abiomed for USD 16.6 billion, solidifying its position in cardiovascular innovation and improving care for heart failure patients.

Drug Class Market Breakdown

The myocardial infarction market can be segmented into the following drug classes:

1. Antiplatelet Agents
2. Glycoprotein IIb/IIIa Inhibitors
3. Antithrombotic Agents
4. Beta-adrenergic Blockers
5. Vasodilators
6. ACE Inhibitors
7. Angiotensin-receptor Blockers
8. Analgesics
9. Thrombolytics

Distribution Channels

The distribution channels for myocardial infarction treatments include:

1. Hospitals
2. Hospital Pharmacies
3. Drug Stores
4. Online Drug Stores

Country-Level Market Overview

The report covers the myocardial infarction market across 25 countries, including the United States, Canada, Germany, France, the UK, China, Japan, India, Brazil, and Saudi Arabia.

Related Reports

Explore more reports on related health topics to stay ahead of market trends:

• Anti-Venom Market Analysis
• Cystic Fibrosis Therapeutics Market Analysis
• Active Pharmaceutical Ingredients (API) Market Analysis

Company Profiles

Some of the key companies driving innovation in the myocardial infarction market are:

1. Pfizer
2. Sanofi-Aventis/Bristol-Myers Squibb
3. AstraZeneca
4. Merck
5. Daiichi Sankyo
6. Eli Lilly and Company
7. Novartis
8. Amgen
9. Bayer
10. Recardio, among others.

About Renub Research
Renub Research is a market research and consulting company with over 14 years of experience. We deliver insights and analysis across industries, helping businesses make informed decisions.

For more information: Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Email: info@renub.com
Address: 225 Kristie Ln, Roswell, GA 30076